SARS-CoV-2 neutralizing antibodies: a network meta-analysis across vaccines

Paola Rogliani MD\textsuperscript{1}, Alfredo Chetta MD\textsuperscript{2}, Mario Cazzola MD\textsuperscript{1} and Luigino Calzetta PhD\textsuperscript{2}\textsuperscript{*}

1. Unit of Respiratory Medicine, Department of Experimental Medicine, University of Rome “Tor Vergata”, Rome, Italy.
2. Department of Medicine and Surgery, Respiratory Disease and Lung Function Unit, University of Parma, Parma, Italy.

*Corresponding author: Luigino Calzetta, Department of Medicine and Surgery, Respiratory Disease and Lung Function Unit, University of Parma, Via Rasori 10, 43126 - Parma, Italy. E-mail: luigino.calzetta@unipr.it
| Section/topic                  | # | Checklist item                                                                                                                                                                                                 | Reported on page # |
|-------------------------------|---|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|
| **TITLE**                     |   |                                                                                                                                                                                                             |                   |
| Title                         | 1 | Identify the report as a systematic review, meta-analysis, or both.                                                                                                                                           | 1 main MS        |
| **ABSTRACT**                  |   |                                                                                                                                                                                                             |                   |
| Structured summary            | 2 | Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number. | 3-4 main MS      |
| **INTRODUCTION**              |   |                                                                                                                                                                                                             |                   |
| Rationale                     | 3 | Describe the rationale for the review in the context of what is already known.                                                                                                                                | 5 main MS        |
| Objectives                    | 4 | Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).                                                       | 6 main MS        |
| **METHODS**                   |   |                                                                                                                                                                                                             |                   |
| Protocol and registration     | 5 | Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.                                             | 7 main MS        |
| Eligibility criteria          | 6 | Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.                                | 7 main MS        |
| Information sources           | 7 | Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.                                                   | 7-8 main MS      |
| Search                        | 8 | Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.                                                                               | 8 main MS; Table S2 |
| Study selection               | 9 | State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).                                               | 8 main MS        |
| Data collection process       | 10| Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.                                      | 9 main MS        |
| Data items                    | 11| List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.                                                                          | 9-10 main MS     |
| Risk of bias in individual studies | 12| Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.  | 11-12 main MS    |
| Summary measures                                                                 | 13 | State the principal summary measures (e.g., risk ratio, difference in means). | 11 main MS |
|---------------------------------------------------------------------------------|----|--------------------------------------------------------------------------------|------------|
| Synthesis of results                                                            | 14 | Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I²) for each meta-analysis. | 11 main MS |
| Risk of bias across studies                                                     | 15 | Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies). | 11-12 main MS |
| Additional analyses                                                              | 16 | Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified. | 10 main MS |

**RESULTS**

| Study selection                                                                 | 17 | Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram. | 13 main MS; Figure 1 |
| Study characteristics                                                           | 18 | For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations. | 13 main MS; Table 1 |
| Risk of bias within studies                                                     | 19 | Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12). | 15-16 main MS; Figure S4 |
| Results of individual studies                                                   | 20 | For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot. | 12 main MS; Figure 2 |
| Synthesis of results                                                            | 21 | Present results of each meta-analysis done, including confidence intervals and measures of consistency. | 14 main MS; Figure 3, 4 |
| Risk of bias across studies                                                     | 22 | Present results of any assessment of risk of bias across studies (see Item 15). | 15-16 main MS; Figure S3, S5 |
| Additional analysis                                                             | 23 | Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]). | 14-15 main MS; Table S3 |
| Section                  | Page | Description                                                                                                                                                                                                 | Main MS |
|--------------------------|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------|
| Summary of evidence      | 24   | Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).                                    | 17      |
| Limitations              | 25   | Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).                                                      | 19      |
| Conclusions              | 26   | Provide a general interpretation of the results in the context of other evidence, and implications for future research.                                                                                    | 20      |

**FUNDING**

| Section | Page | Description                                                                                                                                                                                                 | Main MS |
|---------|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------|
| Funding | 27   | Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.                                                               | 22      |

MS: manuscript.
Table S2. Literature search terms used for OVID MEDLINE. The final search strategy applied to conduct this network meta-analysis is reported at step #29.

| #  | Search strategy                                                                 |
|----|---------------------------------------------------------------------------------|
| 1  | ”BNT162b2”.mp. [mp=ti, ab, tx, ct, sh, ot, nm, hw, fx, kf, ox, px, rx, an, ui, sy] |
| 2  | “BBIBP-CorV”.mp. [mp=ti, ab, tx, ct, sh, ot, nm, hw, fx, kf, ox, px, rx, an, ui, sy] |
| 3  | ”New Crown COVID-19”.mp. [mp=ti, ab, tx, ct, sh, ot, nm, hw, fx, kf, ox, px, rx, an, ui, sy] |
| 4  | ”SARS-COV-2 inactivated vaccine”.mp. [mp=ti, ab, tx, ct, sh, ot, nm, hw, fx, kf, ox, px, rx, an, ui, sy] |
| 5  | ”Sputnik V”.mp. [mp=ti, ab, tx, ct, sh, ot, nm, hw, fx, kf, ox, px, rx, an, ui, sy] |
| 6  | ”Gam-COVID-Vac”.mp. [mp=ti, ab, tx, ct, sh, ot, nm, hw, fx, kf, ox, px, rx, an, ui, sy] |
| 7  | ”CoronaVac”.mp. [mp=ti, ab, tx, ct, sh, ot, nm, hw, fx, kf, ox, px, rx, an, ui, sy] |
| 8  | ”adsorbed COVID-19 inactivated vaccine”.mp. [mp=ti, ab, tx, ct, sh, ot, nm, hw, fx, kf, ox, px, rx, an, ui, sy] |
| 9  | ”NVX-CoV2373”.mp. [mp=ti, ab, tx, ct, sh, ot, nm, hw, fx, kf, ox, px, rx, an, ui, sy] |
| 10 | ”AZD1222”.mp. [mp=ti, ab, tx, ct, sh, ot, nm, hw, fx, kf, ox, px, rx, an, ui, sy] |
| 11 | ”ChAdOx1 nCoV-19”.mp. [mp=ti, ab, tx, ct, sh, ot, nm, hw, fx, kf, ox, px, rx, an, ui, sy] |
| 12 | ”Ad5-ncov”.mp. [mp=ti, ab, tx, ct, sh, ot, nm, hw, fx, kf, ox, px, rx, an, ui, sy] |
| 13 | ”Ad26.COV2.S”.mp. [mp=ti, ab, tx, ct, sh, ot, nm, hw, fx, kf, ox, px, rx, an, ui, sy] |
| 14 | ”JNJ-78436735”.mp. [mp=ti, ab, tx, ct, sh, ot, nm, hw, fx, kf, ox, px, rx, an, ui, sy] |
| 15 | ”Ad26COVS1”.mp. [mp=ti, ab, tx, ct, sh, ot, nm, hw, fx, kf, ox, px, rx, an, ui, sy] |
| 16 | ”VAC31518”.mp. [mp=ti, ab, tx, ct, sh, ot, nm, hw, fx, kf, ox, px, rx, an, ui, sy] |
| 17 | ”CoVLP”.mp. [mp=ti, ab, tx, ct, sh, ot, nm, hw, fx, kf, ox, px, rx, an, ui, sy] |
| 18 | ”mRNA-1273”.mp. [mp=ti, ab, tx, ct, sh, ot, nm, hw, fx, kf, ox, px, rx, an, ui, sy] |
| 19 | ”INO-4800”.mp. [mp=ti, ab, tx, ct, sh, ot, nm, hw, fx, kf, ox, px, rx, an, ui, sy] |
| 20 | ”COVISHIELD”.mp. [mp=ti, ab, tx, ct, sh, ot, nm, hw, fx, kf, ox, px, rx, an, ui, sy] |
| 21 | ”RBD-dimer vaccine”.mp. [mp=ti, ab, tx, ct, sh, ot, nm, hw, fx, kf, ox, px, rx, an, ui, sy] |
| 22 | antibody*.mp. [mp=ti, ab, tx, ct, sh, ot, nm, hw, fx, kf, ox, px, rx, an, ui, sy] |
| 23 | 3 or 4 |
| 24 | 5 or 6 |
| 25 | 7 or 8 |
| 26 | 10 or 11 or 20 |
| 27 | 13 or 14 or 15 or 16 |
| 28 | 1 or 2 or 9 or 12 or 17 or 18 or 19 or 21 or 23 or 24 or 25 or 26 or 27 |
| 29 | 22 and 28 |
Table S3. A subset analysis via SUCRA performed according with the age of recipients and the type of candidate SARS-CoV-2 vaccines.

| Type of candidate vaccine                  | Age of recipients |       |       |
|-------------------------------------------|-------------------|-------|-------|
|                                           | ≤60               | ≤70   |
| mRNA-based                                | Quartile          | SUCRA | Quartile | SUCRA |
| 2nd                                       | 0·734             |       | 2nd     | 0·720 |
| Adenovirus-vector-based                   | 2nd               | 0·668 | 2nd     | 0·652 |
| Inactivated SARS-CoV-2                    | 2nd               | 0·652 | 2nd     | 0·664 |
| Plant-derived virus-like particle          | 3rd               | 0·462 | 3rd     | 0·476 |
| SARS-CoV-2 recombinant spike glyc coprotein nanoparticle | 3rd               | 0·440 | 3rd     | 0·448 |

SARS-CoV-2: severe acute respiratory syndrome coronavirus 2; SUCRA: surface under the cumulative ranking curve analysis.
Table S4. AUC, time to peak, and $t_{1/2}$ analyses of neutralizing antibody response to candidate SARS-CoV-2 vaccines investigated for 4 weeks post last inoculation in healthy recipients $\leq 60$ years of age.

|                  | Ad26.COV 2.S | Ad5-nCoV | AZD1222 | BBIBP-CorV | BNT162b2 | CoronaVac |
|------------------|--------------|----------|---------|------------|----------|-----------|
| AUC              | 26·3±23·8    | 11·0±20·0 | 52·7±21·5 | 42·0±17·4 | 37·2±18·7 | 28·2±18·6 |
| Time to peak     | 29           | 28       | 14      | 28         | 7        | 28        |
| (days post last  |              |          |         |            |          |           |
| inoculation)     |              |          |         |            |          |           |
| $t_{1/2}$ (days  | 14           | 14       | 6       | 8          | 4        | 7         |
| post last        |              |          |         |            |          |           |
| inoculation)     |              |          |         |            |          |           |

Data are reported as mean±SEM. AUC: area under the curve; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2; SEM: standard error of the mean; SMD: standardized mean difference; $t_{1/2}$: onset of action.
Figure S1. Overall ranking plot of subset analyses displaying the efficacy of candidate SARS-CoV-2 vaccines at inducing peak neutralizing antibody response in vaccine recipients ≤60 years of age (A) and ≤70 years of age (B). Vaccination strategies were plotted on X-axis according to SUCRA, where 1 results for a vaccine considered to be the best, and 0 for a vaccine considered to be the worst. SARS-CoV-2 vaccines were plotted on Y-axis according to the rank probability of best vaccine, where a score of 1 is assigned to the best vaccination strategy. SARS-CoV-2: severe acute respiratory syndrome coronavirus 2; SUCRA: surface under the cumulative ranking curve analysis.
Figure S2. Neutralizing antibody response to candidate SARS-CoV-2 vaccines monitored across different time-points post inoculation vs. baseline in healthy volunteers ≤60 years of age. SMD: standardized mean difference.
Figure S3. Weighted plot for the assessment of the overall risk of bias via the Cochrane RoB 2 tool (n=11 clinical trials). RoB 2: Risk of Bias 2.
**Figure S4.** Traffic light plot for assessment of the risk of bias of each included clinical trial via the Cochrane RoB 2 tool. D1: bias arising from the randomization process; D2: bias due to deviations from intended intervention; D3: bias due to missing outcome data; D4: bias in measurement of the outcome; D5: bias in selection of the reported result. RoB 2: Risk of Bias 2.
Figure S5. Publication bias assessment via the normalized consistency/inconsistency plot (linear regression and 95% prediction bands) of different SARS-CoV-2 vaccines with respect to the peak level of neutralizing antibodies. SARS-CoV-2: severe acute respiratory syndrome coronavirus 2.